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Abstract
Palliative care is an essential component in any disease management. Pain 
assessment acts as the connecting link between the nerves, brain and spinal cord. 
Classification and assessment of the pain have great significance in controlling 
the pain-related symptoms. Pain is broadly divided into three types nociceptive, 
neuropathic and mixed depending upon the damage caused. Nociceptive pain is 
caused due to the stimulation of the pain receptors in the tissues and is further 
divided into visceral and somatic depending on the pain site. Neuropathic pain 
arises when the nervous system gets damaged or start dysfunctioning. Cancer pain 
assessment includes several factors like the site, intensity, syndrome, timing and 
temporal variation of pain. Edmonton staging system for cancer pain prognostic 
is widely used for pain management includes emotional/psychological distress 
cognitive impairment caused by pain. A comprehensive understanding of pain 
assessment will help in enhancing the quality of life of the patients.
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1. Introduction
Pain is broadly defined as the unpleasant sensations in the body resulting due 
to the complex experience of various factors like physical, psychological and 
emotional [1]. Pain is subjective as pain tolerance differs from person to person. 
Pain cannot be quantified as it is associated with the effective as well as sensory 
components. Most cancer patients claim pain as the most common symptom 
and are quite dreaded, a major cause of anxiety [1]. Palliative care is an essential 
component in disease management. Good pain management is an important step 
towards palliative care. First of all, it is very important to understand the cause of 
pain, then assessment and manage pain, finally reassessment and monitoring the 
factors resulting in the pain. Managing and correct assessment of these symptoms 
are important for the wellbeing of the person to whom palliative care is being given.
It is very important to note that palliative care is intended to provide quality 
life by symptom control. To accomplish this, it is must to classify and assess the 
effects of pain. Pain is classified into various categories depending upon the 
duration, location, intensity and etiology of the pain (Figure 1). Pain can be acute 
or chronic depending on the duration of the pain. Acute pain is not long-lasting 
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as it gets resolved within a short duration whereas pain that cannot be resolved 
within six months is considered chronic pain. Chronic pain is further of three types: 
non-cancer, cancer and episodic. The intensity of pain ranges from mild to severe. 
Pathophysiology is mostly done by the utilization and knowledge of the damage 
caused to the tissue (nociceptive) and nerve (neuropathic) or could be unlocalized 
(visceral) or break-through that was given by the International Association for 
the Study of Pain (IASP) [2, 3]. It is noteworthy that pain can be physical as 
well as emotional. European Association for Palliative Care (EAPC) conducted 
an extensive review on the management of the use of pain assessment tools in 
palliative care research [3–5]. The newly revised version of cancer pain prognostics 
has included emotional/psychological distress, cognitive impairment caused by 
pain in the Edmonton staging system for cancer pain [4]. This improvement in 
pain prognostics has been able to be predictive than the previous methods used by 
IASP [3]. There are methods for the staging and progression of cancer like TNM 
Classification of Malignant Tumors (TNM). Unfortunately, there is no consensus 
on a single standardized tool for pain assessment [6]. The reason behind this is the 
varied nature of cancer and its malignancy and different perceptive and tolerance 
of pain in patients [6, 7]. Also, to blame is less predictability of the nature of tools 
available, as sometimes the mechanisms are not well known. To work on this 
problem, an extensive literature study on the physical, medical, psychological 
background and education on self-awareness/acceptance of pain should be deemed 
feasible.
2. Cause of pain
2.1 Nociceptive pain
It is also known as momentary pain. It is a form of acute pain caused by the 
triggering of nociceptive nerve receptors. This triggering occurs as a result of 
damaging chemicals or inflammation in the region [8]. A great example will 
be hitting your head on the table or stubbing your toe. Generally, nociceptive 
pain location is local. This type of pain gets notified by the nociceptors present 
throughout the skin and the internal organs. They can detect any chemical or 
physical damage send through the nervous system for immediate action [9]. There 
are two types of nociceptors as suggested by F. Cervero in 1985; one of them works 
for the fast transmission of pain called A-delta fibers whereas another one that 
slowly transmits pain is C–fibers [8]. The unmyelinated structure of C-fibres 
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or mechanical stress [8]. Increased abnormal sensitivity to the pain or chemical 
stimulus is named hyperalgesia caused by inflammation in the area [8–10].




This type of pain arises from the stimulation of the nerve cells in the tissue such 
as skin, bones muscles, etc. due to damage [11]. Based on the site of cause the person 
can have superficial or surface-level deep somatic pain in bone or tendons and this 
type of pain comes in a flash as the injury is sustained [9, 11]. Due to the two varied 
nature of this pain person suffering from superficial pain will have an easier go at 
finding and pinpointing the pain rather than the deep somatic pain which is much 
harder to pinpoint as it diffuses easily and tends to radiate.
2.1.2 Visceral pain
Visceral pain occurs in cases when the person suffers from damage to the 
internal organs such as the intestine etc. The sensation of pain can be caused 
by damage to the tissue by external force or extensive pressure caused due to 
oncological reasons or infection in the abdominal organs [4, 8, 12]. This pain is 
not easy to pinpoint as the patient feels dull and as if squeezing most of the time 
due to the scarcity of the nociceptors [4]. Feeling in the area of damage detected 
by the nociceptors present in the abdominal cavity and on the organs it doesn’t 
have a sharp onset visceral pain [8]. This effect is also termed as viscero-somatic 
convergence where the pain signal transported by afferent nerves converge with the 
nerves that are transferring pain from the say skin area can cause side effects such as 
nausea vomiting etc. [12].
2.2 Non-nociceptive pain
2.2.1 Neuropathic pain
This type of pain is characterized by the damage or improper function/misfiring 
of the neurons. The IASP defines neuropathic pain “pain initiated or caused by a 
primary lesion or dysfunction in the peripheral or central nervous system. A study 
by Martin, L. A., & Hagen, N. A. (1997) broadly classified them into peripheral 
and central neuropathic pain. Peripheral neuropathic pain has many sub iterations 
depending on the nerves involved. In a case study done by them, it was stated that 
out of 72 patients, six of whom had benign tumors, suffered central neuropathic 
pain [13]. This study concludes that the nerves that get damaged will start firing 
erratically with or without any nociceptive signal. Patients suffering from such 
chronic pain have reported that they experience pain constantly and are shooting in 
nature [13]. The pain can be triggered by a small number of stimuli or even without 
any stimuli. Multiple reports and studies suggest that hyperactivity of damaged 
neurons and further release of neurotransmitters, inducers, modulators, increase 
the effect [2, 10, 14]. Also, it is noted that the person’s immune response to the pain 
releases cytokines which also elevate the neuropathic pain. Diseases such as diabe-
tes, chronic back pain, alcohol consumption, cancer stroke are some reasons for this 
type of pain. The sympathetic nervous system can lead to the increased sensitivity 
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of the nerves. The release of hormones during flight/fight response increases 
awareness and due to this the nerves also get more sensitized leading to such pain 
suggested by Gierthmühlen, J. and R. Baron in 2016 [10].
2.2.2 Psychological effect on pain
Psychological factors are the major players in how the patient perceive the pain. 
Factors such as initial awareness, emotional status, interpretation and processing of 
pain and coping strategy play an important role in the perception of the pain [15]. 
Research on the effect of psychology and mental state by S.J. Linton and W.S. Shaw 
defines that initial detection of pain plays a crucial role in building up the psycho-
logical effects of it [16]. It is noted that pain needs attention and it is mostly under 
our conscious control. If the pain is deemed a threat, the autonomous nervous 
system kicks in, and also for later stages the object is likely to be avoided. Emotional 
state and interpretation can play a major role in sensitization and interpretation 
of pain [16]. Pain behaviour can be linked to how the person interprets the pain 
while suffering from it like verbal or non-verbal action and also after suffering 
from pain like the patient may start avoiding the source of stimuli as it generates 
the fear response. Negative thoughts about life such as anxiety, depression and fear 
can negatively affect the perception of pain and this may consequence in not only 
increasing the intensity but also prolonging the pain. Studies such as in S.J. Linton 
and W.S. Shaw in 2011 have shown 52% of people suffer from such a negative 
emotional state during pain [16]. Patients with imminent fear of the future also fall 
in this category and this all consequences in poor rehabilitation of the patient [15]. 
The next stage comes to coping with the pain, it has been seen that painful stimuli 
trigger the flight response with epinephrine released that can greatly affect the 
sensation of pain. [15, 16]. It can be inferred by this that in both cases, the sensation 
seems to be more tolerable as the person either avoids pain or confronts the source. 
The other method that seems to work is having a relaxed state of mind. Effects such 
as phantom limb pain are still considered to be a psychological phenomenon [17, 
18]. Even though the limb does not exist, the pain is still perceived. In all, pain is 
greatly affected by the mental state of the person, but it has to be well understood 
and more studied.
3. Tools for analysing pain intensity
Pain intensity is subjective from person to person hence a common ground 
is picked which either in pictorial form or in the form of a questionnaire is 
communicated between the patient and the caregiver where the caregiver gets an 
idea of the situation and can plan before the treatment. These pain intensity tools 
play a major role in the assessment of pain and the tools used to analyze. There are 
many tools, but few are used quite often such as the McGill pain questionnaire, 
Wong-baker face pain scale, (Figure 2) visual analogue and numerical scales 
(Figure 3). Much of them work in a similar method by presenting the patient with a 
pictorial or a numerical based scale that the person can relate to and the person can 
pinpoint on which part of the scale he/she thinks the pain suffered stands [7].
3.1 Unidimensional pain assessment tools
The unidimensional assessment tool consists of mainly 2 categories which 
include the visual analogue scale or numerical rating scale and the pictorial rating 
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scale. These may or may not include verbal descriptions of the pain such as - moder-
ate, severe, or less pain. In the visual analogue and the numerical method of scaling, 
a patient is asked to choose and mark the word or the number they compare/relate 
their pain to [17, 19]. The other method is utilizing the pictorial representation 
(Figure 2) such as faces which utilizes the comical representation of the reactions 
suffered during pain this method is best suited for children as it is difficult for them 
to translate a sensory experience to a spot on the scale example of such pictorial 
scale is Wong-baker face pain scale which utilizes 6 facial expressions describing the 
severity of pain [7].
The drawback of these methods is that these methods rely on the opinion of 
the patient and the opinion may vary due to different pain tolerance limits in dif-
ferent patients to the same pain sources [7]. Tolerance of a patient can be judged 
for a specific area using a dolorimeter which uses heat, electricity, or pressure 
to analyze the sample area’s sensitivity and this can be later noted for further 
scaling [7].
3.2 Multi-dimensional pain assessment tools
As the name implies this type of tool assesses a patient on different levels/
dimensions compared to the unidimensional pain assessment method. The Multi-
dimensional method includes an assessment of more features such as the impact of 
pain, quality of pain and phenotype of pain for example to determine whether the 
person is suffering from neuropathic pain or not [19]. These tools utilize different 
types of the questionnaire to achieve its goal such as determining the impact and 
screening of the pain.
Figure 2. 
Visual analogue pain intensity scale. Patient has to pin-point on where their pain stands on the scale [7].
Figure 3. 
Wong-baker face pain scale. The physician and the patient can look and state which expression they feel 




Brief Pain Inventory (BPI).
McGill Pain Questionnaire (MPQ ).
Neuropathic Pain Scale (NPS).
Pain Quality Assessment Scale (PQAS).
Leeds Assessment of Neuropathic Symptoms and Signs (LANSS).
Neuropathic Pain Questionnaire (NPQ ).
Douleur Neuropathique en 4 Questions (DN4) [20, 21].
3.2.1 Brief Pain Inventory (BPI)
BPI was developed by Collaborating Centre for Symptom Evaluation in Cancer 
Care, a team of WHO [22]. This is a method incorporated to assess self-reported 
pain severity and any interference in daily functioning, used in both clinical and 
research settings and is widely utilized and recognized in cancer pain assessment 
it is being self-administered and easy to access [7, 20, 23, 24]. It was approved and 
translated into many languages including Hindi, Spanish, Brazilian, etc. [22]. The 
subject is asked to fill up nine questions like if they have been feeling pain recently, 
location of the pain (a pictorial representation of both dorsal and ventral side of 
the human body which the subject can use to highlight the area of distress), pain 
intensity/severity during different intervals and other questions may include 
the effect of the drugs like an opioid taken for medication for pain management 
and lastly how pain affects your mood and your daily routine [25]. The scoring 
is divided into two categories that are pain severity and pain interference with a 
score of 0–10 where zero being no pain and ten being severe [25]. Similar scaling 
is done for interference also the final scoring is 0–40 and 0–70 respectively [25]. 
Multiple studies suggest that this two-dimensional tool (BPI) is quite adequate and 
is a capable method in analyzing pain intensity and pain interference caused due 
to neuropathic and nociceptive pain. In cancer pain assessment such as in a study 
conducted with 199 patients who underwent radiotherapy and results showed that 
there is a good correlation with an increase in pain intensity and its interference in 
the daily routine after radiotherapy [22].
3.2.2 Neuropathic Pain Scale (NPS)
As the name suggests it is a scale that is utilized for the differentiation in the 
neuropathic and non-neuropathic pain developed by Galer and Jensen [26, 27]. 
This scale contains 11 items for judging the qualitative and quantitative aspects 
of pain [20]. These items include pain intensity and its effect some items help in 
determining the features of the neuropathic pain such as sharpness, sensitivity, etc., 
and also how deep the pain is [28]. These items help in drawing a more accurate 
picture of the location and the quality of the pain widely utilized in the diagnosis of 
multiple sclerosis [20, 27, 28].
3.2.3 Pain Quality Assessment Scale (PQAS)
It is also a multidimensional scaling tool with questions that are explained 
descriptively such as sensitivity etc. In case of severity of pain, a numerical rating 
from 1 to 10 with ten being severe pain. The patient is advised to fill up/mark 
answers to the questions based on 20 items. These queries were recently revised 
by Mark P. Jensen in a cognitive revision test of the items to make them more 
understandable by the patients [21].
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3.2.4 Leeds Assessment of Neuropathic Symptoms and Signs (LANSS)
LANSS was developed to address the less reliability of the NPS in neuropathic 
pain. This tool has a self-reportable version similar to BPI called S-LANASS 
with seven elements each weighted differently and is readily used in cancer pain 
assessment [20, 26, 27, 29]. Five questions mostly deal with yes or no questions for 
the severity, location, sensitivity, duration, etc. The last two questions are activity-
based and require certain diagnostic actions such as gentle touching/rubbing the 
painful area [26, 29, 30]. These help in deducing if there is any nerve dysfunction, 
the final scoring is given by 24 [26, 29]. If the person receives a general score of less 
than 12 the pain is designated in the nociceptive section if the scoring is greater than 
12 then the person falls in the category of neuropathic or Pain of Predominantly 
Neuropathic Origin (POPNO) [29, 30]. Originally designed by Michael Bennett 
has now been translated to many languages such as German Turkish, Chinese and 
even in Malayalam. It confirms the validation of this tool 101 chronic pain suffering 
patients were brought of which fifty patient were nociceptive and fifty-one were 
neuropathic the test concluded with a Cohen’s Kappa 0.743(is a statistical analysis 
to test the reliability of a test with a range of −1 to +; generally >0.70 values are 
considered substantial) with 89.5% sensitivity [29, 31].
3.2.5 Neuropathic Pain Questionnaire (NPQ )
This is another method for judging and differentiating neuropathic pain from 
non-neuropathic pain [20]. A test regarding the validation on 528 chronic pain 
suffering patients of which 149 of them with neuropathic symptoms they were 
asked to fill up the NPQ with 12 items with the last 2 related effect of pain [32]. It 
was noted that it had a very low-reliability rate (66% sensitivity only) because of 
which it is not much popular as compared to the others [20, 30, 32]. Hence, it has 
been mainly used in the initial screening of neuropathic pain [20].
3.2.6 Douleur Neuropathique 4 Questions (DN4)
A ten-item scaling method utilized in the characterization of neuropathic pain 
has 4 questions that are simple to attempt with validated cognitive tests to prove its 
understandability to the patients it is administered to [21]. It has been translated 
into many languages and has a sensitivity of 83% [20].
3.2.7 McGill Pain Questionnaire (MPQ )
McGill pain questionnaire established by Dr. Melzack and Torgerson in 1971 
at McGill University in Montreal, Canada is widely used in assessment tools for 
monitoring the intensity of pain [7]. Many studies have been conducted on the 
questionnaire such as by B Nicholson suggesting that it is a documentation method 
that utilizes the patient’s experience like how he feels the pain, duration site, etc. 
[3, 7, 14]. A survey done by P. Kumar et al. showed that a total of 297 patients who 
underwent MPQ reported that it was qualitatively and quantitatively satisfying [7]. 
It gives multiple choices that help in identifying and in relating the pain suffered 
by the patient and these can be later compared with changes in a longer period of 
monitoring the patient [7, 14]. Not only that it also gives a human diagram to point 
out wherein the body the pain exists. With questions such as where your pain is? Is 
it internal or external? And the multiple-choice for how the pain changes with time, 




4. Methods of pain assessment (pain assessment tools)
Assessment is the rigorous process of documentation, self-knowledge and 
interpretation. The need for cancer pain assessment during and after the treatment 
at the end-of-life stage is very important. Many contributing factors may affect 
the diagnosis of the source of the pain. Due to the varied nature complexity in the 
classification of pain, there is no consensus on a common pain assessment tool. This 
is to be noted and a common effective method should be there to evaluate the pain 
and its history in the patient. Since the pain assessed is in the boundary of cancer, 
the method to stage malignancy and its type is measured by TNM classification of 
cancer. Since its discovery, it has been proficiently helping in the further planning 
of treatment to be provided. With the staging ranging from 1 to 4 with the fourth 
being severe [3, 6]. TNM staging plays an important role in the assessment of the 
pain as it can convey information about size, if it is malignant or if it has spread into 
the lymph [6]. Similarly, widely used pain assessment tools are
• International Association for the Study of Pain -IASP assessment tool for 
chronic pain taxonomy
• Edmonton classification system for cancer pain -ECS-CP
• Cancer pain prognostic scale-CPPS [3].
• Alberta breakthrough pain assessment tool [33–36].
4.1  International Association for the Study of Pain (IASP)- Assessment Tool for 
Chronic Pain Taxonomy
It is a symptom sign-based type of deducing the effects of chronic pain in the 
patient. It is the list of diseases that provide information and classification of pain. 
Studies on the basis of the location of occurrence the pain, where it is present in 
the body. Next comes how the patient feels the pain like it is pinching, radiating or 
may be flickering in nature or does it change as time passes. This helps the clinical 
person to deduce the type of pain whether neuropathic or nociceptive and also 
possible organ system that is affected by the pain by deducing if it is visceral or 
somatic. The last consideration taken is the intensity of the pain [3, 14]. To extract 
this information, the patient is asked to fill up a questionnaire such as the McGill 
pain questionnaire which deals with [7, 14]. The problem with such classification of 
pain is that it is not predictive in similar aspects to TNM which is predictive and can 
give an idea on how to plan the treatment [3, 6]. Due to much-received criticism, 
changes were done in 2011 namely, the International Classification of Disease 
11th revision (ICD -11) was for chronic pain groups such as chronic cancer pain 
involving the use of visceral and neuropathic pain and also adding continuous pain 
and episodic pain (pain that comes and goes) [2].
The IASP classification of chronic pain is done by using these following 
groups/ domains
Domain 1-The site where the pain occurs
Domain 2-Organ systems that get affected due to pain
Domain 3-Temporal characteristics deal with the frequency of pain
Domain 4-Intensity of the pain and time passed since its onset
Domain 5-Pain etiology [3].
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4.2 Cancer pain prognostics scale
It is a numerical-based scale for characterizing and for running prognostic 
assessment of the condition and it is more predictive as compared to the previous 
ones. It is based on the scores ranging from 0 to 17, where the higher the scoring 
on this scale the good/better the prognosis and better chances of pain relief. 
Hence, this is a very useful tool in determining poor prognostics amongst 
patients [2]. This scaling has added features compared to IASP assessment for 
pain such as
Domain 1-Worst of pain
Domain 2- Emotional well-being of the patient
Domain 3- Pain characteristics
Domain 4- Daily opioid consumption [3].
Where scaling for worst pain is given from 1 to10, for emotional well-being is 
judged by using Functional Assessment of Cancer Therapy (FACT-G) and the daily 
opioid dose is monitored for greater than 60 mg consumption as its higher levels of 
it will make it difficult to control pain and person seems to be more tolerant [3].
4.3 Edmonton classification system for cancer pain (ECS-CP)
To improve on the IASP system of classification for chronic pain, there is a 
better versed and more widely accepted method of classification called ECS-CP 
(Edmonton Classification System for Cancer Pain) also is incorporated in the 
multisite of European Palliative Care Research Collaborative (EPCRC) [3, 4]. It is 
a more rigorous and user-friendly system of pain classification compared to the 
previous iterations for classifying pain. Additional descriptive features for pain 
classification are also incorporated such as the patient’s emotional wellbeing. Other 
than this it incorporates seven components to evaluate the patient as suggested by 
Bruera E.[4]:
Domain 1-Mechanism of pain
Domain 2- Characteristics
Domain 3- Cognitive function
Domain 4- Previous opioid use
Domain 5-Psychological distress
Domain 6- Tolerance
Domain 7-History of such related pain [2, 4, 37].
Hence it is implied that this is better for further prognosis and pain treatment as 
this not only keeps check on the emotional/psychological distress but also considers 
the patient history of having difficulties in the same area or maybe similar types of 
pain [2, 4, 37]. Also, to be noted that it also checks whether if there is any case of 
taking opioids and if due to pain there is any cognitive impairment in the concerned 
patient though their involvement is still debated in the process of pain assessment 
in the newer version of this model. This method of assessment and prognosis of 
pain has widely been reviewed and validated in many studies and there is still 
improvement going on.
ECS-CP questionnaire categories are further dived into subcategories such 
as the understanding mechanism of pain it can be divided into the following 
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No Distress Yes, Present







3 No Pain Felt No Incident 
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Specify if, Psychological distress is present: _________________________________________________________
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category and subcategory can be in small caps alphabetic or numerical, the 
lower sub-feature as seen provides more information higher the chances of good 
prognosis. Similarly, for the rest of the groups depending on the new version such 
as opioid intake, tolerance, they are also divided into subcategories according to 
their function [2, 4].
4.4 Alberta breakthrough pain assessment tool (ABPAT)
ABPAT was developed by Alberta Cancer Board and the Alberta Cancer 
Foundation. It is an emerging tool for pain prognostics and works under the 
boundaries of assessing breakthrough pain. This method was developed by 
a knowledgeable panel of the reviewer by utilizing the Delphi process and 
conducting many patient’s think-aloud interviews [34, 36] Breakthrough pain is 
generally categorized as a sudden increase or flaring of existing chronic pain such 
as in cases of cancer or joint-related problems [33]. It is reported that breakthrough 
pain in cancer patients, its occurrence is about 40–93%, hence quite common as it 
has come up quite a lot of times that no standardized assessment tool exists so the 
goal of Alberta breakthrough pain assessment tool was to provide a standardized 
format for research purposes [34]. Using the opinion of experts in this field 
reaching a consensus a questionnaire of 17 questions was put out. Next came the 
validation of this process, whether the patients were understanding what they 
have been asked to fill up so that the researcher added the think-aloud to judge 
the comprehensive and cognitive understanding of the people participating in the 
survey (Figure 4). This helped in the revaluation of their question by rigorous 
feedback from the participants and adding any changes in between.
The format of questions participants was asked:
• Relationship to the baseline pain
• Location and intensity of pain
• Quality, duration and frequency of pain
• Predictability of pain
• Response to medication [34].
This was well evaluated in a study conducted that was mentioned by Sperlinga 
R. where approximately 90% of the participants said that the questions were 
understandable and 80% said that it is a good tool for the breakthrough problem 
[35]. The validation and reviewing of the results were done both nationally and 
internationally such as in UK, Australia, Middle-East, Israel and North America 
and many respondents that participated in the survey were from medical nursing 
fields [34].
4.4.1 Why pain arises?
Pain is the 3rd most common symptom of cancer and reportedly has many 
reasons for the cause of pain from cancer [38]. It winds up being the patient-related 
factors such as, the location of the tumor, the neural system and the tissue being 
affected, stage of cancer its malignancy etc. People also suffer from pain related 
discomfort while going through the treatment of cancer which includes surgery for 
the removal of the tumor from the affected area, chemotherapy and radiotherapy 
Palliative Care
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that the patient may be undergoing for managing cancer [39]. Hence cancer pain 
can be broadly divided into two categories
1. Pain caused due to tumor
2. Pain caused while undergoing treatment
Tumor related cancer pain mainly occurs due to excessive pressure on the nearby 
tissue or bone (Cancer-induced bone pain) and nerve causing the sensation of pain. 
Also, this can lead to blockages to a certain area and bodily mechanism of transport 
of nutrients, causing tissue damage which can cause both nociceptive pain and 
neuropathic pain if the nerves are damaged [38, 40]. Inflammatory responses can also 
be a major player in destroying affected areas such as in a study related to pancreatic 
cancer. It was noted that due to inflammation transient receptor potential cation 
channel gets activated which in turn activates Substance P (SP) and Calcitonin Gene-
Related Peptide (CGRP) two neurotransmitters that transfer pain signals to dorsal 
root ganglia [38]. In the case of cancer-induced bone pain, cancer cells release RANKL 
(Receptor activator of nuclear factor kappa-B ligand) which increases the reabsorp-
tion of the bone by osteoclasts degrading the bone and sensitizing pain nerves [41, 
42]. Drugs that are used in the treatment of neoplastic disease(chemotherapy) such 
as Bortezomib, Cisplatin, Vincristine, etc. although are widely used and effective but 
have a big downside of causing peripheral neuropathy by damaging sensory neurons, 
dorsal root ganglia and neurons present in the spinal cord [40]. Surgical procedures 
cause side effects in many cases and may have minor damage to the operated area. 
This can lead to neuralgia due to damaged nerve or in one study on myofascial pain 
syndrome caused after post breast cancer surgery. The neuromuscular damage after 
breast cancer surgery in the thoracic area stays contracted in pressure and is sensitive 
to myofascial trigger points [39, 43]. Even patients who are undergoing radiotherapy 
for head neck cancer have reported that radiotherapy results in other problems like 
mucositis in their buccal cavity and their throat and esophageal tract with severe 
lesioning [44]. These studies suggest that cancer pain can not only be caused by the 
tumor but also by the treatment that the person is undergoing.
Figure 4. 
Flowchart representing research design for ABPAT [34].
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4.4.2 Treatment and management
The best and widely accepted treatment in cancer pain is the utilization of 
opioids which are predominantly used for symptomatic treatment of pain [45]. 
Opioids function by binding to opioid binding receptors such as (mu, kappa, 
delta, and sigma) and these ligands and receptors are present throughout the body. 
Opioids function as inhibitory agents during excitation and in turn decreases 
the release of excitatory neurons [46]. Morphine is the most well-known among 
opioids [41]. These opioids such as buprenorphine, codeine, fentanyl, methadone, 
oxycodone, and tramadol are given in various methods such as oral, intravenous 
injection or drip, etc. The amount of dosage to be given is determined by the body-
weight of the subject [46]. Various drugs have their benefits like fentanyl which can 
be used for rapid action in cases of oral administration it is also good for delivering 
transdermally including opioid buprenorphine [45]. Other methods include the 
administration of corticosteroids for anti-inflammatory effects. In the USA, this 
method is used against inflammation caused by cancer and related treatments 
in palliative care [47]. Similarly, the utilization of aspirin as a non-steroidal drug 
is also widely administered [47]. Recently due to much increase in cancer pain 
research, the analgesic abilities of marijuana (cannabinoids) are also being looked 
upon as a potential drug for pain mitigation. Another drug “oliceridine” which 
was recently approved in 2020 for cancer pain management in adults was found 
to have fewer side effects as it also activates G- coupled protein receptor based 
μ-opioid receptor and has therefore an analgesic effect with tolerance comparable 
to morphine [42, 48]. In cases where analgesic medicines are deemed ineffective, 
gabapentin or pregabalin are recommended for low dosage use.
Although opioids are well suited and effective against nullifying the effects of 
pain. Although, it has been well documented that if abused, they do have detrimen-
tal effects on the patient with higher doses having the possibility of addiction and 
then withdrawal from the drugs. Short-term effects still include nausea, vomiting, 
breathing difficulties and many more [46, 49]. This was validated by a study done 
by Kata V. on opioid abuse stating that in 2016 one of the top causes of accidental 
death in the U.S was opioid drug overdosing [49]. In the same study, it was also 
noted that due to breakthrough cancer pain requiring short-acting opioids and are 
required in frequent doses compared to long-acting opioids this can cause overdos-
ing of the patient leading to complications [49]. A long-proposed idea is the use of 
non-opioids and non-steroidal anti-inflammatory drugs. In a study conducted by 
Janette Vardy and Meera Agar, they mentioned that multiple studies and research 
on more than 2000 patients were conducted and these patients were administered 
with acetaminophen [50]. It was noted that at various doses of acetaminophen 
ranging from 500–1000 mg, there was significant reduction in pain and there was 
no ill effect about the same. Furthermore, nonsteroidal anti-inflammatory drugs 
can become toxic in patients with cardiovascular and GI tract issues, indicating 
that even they have to be administered only after checking for these ailments on the 
patients [50]. For further research, proper mitigated administration of these pain 
repressing drugs should be followed.
5. Conclusion
Still, pain assessment remains quite challenging to the caregivers. The reasons 
being first there is no consensus available or a format that speaks a common 
language to the masses. Pain acts differently in individuals and even though two 
people suffer from the same ailments their pain tolerance will be affected by many 
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environmental and genetic factors. Differences in the site, the comprehension 
and pinpointing of the pain, the varied nature in intensity and the change in the 
same intensity due to previous/ongoing emotional turmoil, rendering the use of 
the same type of method for each obsolete. Many of the assessment tools are either 
disregarded or are still under heavy reviewing by peers. Some such as the IASP tool 
for assessment are unable to predict the future movement of pain symptoms and 
their debilitating effect. Though the ECS-CP, CPPS and ABPAT can predict to some 
extent they are not on par with the basic TNM staging of cancer. The intensity of the 
pain is very subjective and will vary from patient to patient.
The major problem of pain assessment is the subjective nature. The addition of 
emotional and psychological effects has been shown to produce more correlation 
between the subjective and the documented results and this will help in predicting 
the future pathway, the pain may take. Though this has been accomplished by the 
commonly accepted ECS-CP & CPPS but extensive review and research should 
be conducted such as in ABPAT with international validation (though it is still 
on-going). Also, assessment tools rather than being rigid can be multi-dimensional 
and include more domains specifically catering to the patient. This will not only 
provide a proper prognostic to the patient, but the caregiver will also be more 
prepared to administrate the required amount of analgesic /opioids to not only 
treat pain symptoms but also preventing any such overdosing of the drugs. And 
maybe increase the administration of drug alternatives that are not addictive such 
as non-opioids and nonsteroidal anti-inflammatory drugs. Hence, hopefully, this 
multi-dimensional pain assessment method might able to provide a smoother life 
during the patient’s palliative care stage.
Acknowledgements
Sonika Charak is thankful to National Brain Research Centre for providing 
financial assistance. Chandra Mohan Srivastava and Manish Shandilya would like 
to acknowledge the support provided by Amity University Haryana for financial 
assistance.
Conflict of interest
The authors declare no conflict of interest.
15
Assessment and Management of Pain in Palliative Care
DOI: http://dx.doi.org/10.5772/intechopen.96676
Author details
Sonika Charak1, Robin George Thattil2, Chandra Mohan Srivastava2,  
Prabhu Prasad Das3 and Manish Shandilya2*
1 National Brain Research Centre, Manesar, Gurugram, Haryana, India
2 Amity School of Applied Sciences, Amity University Haryana, 
Gurugram, Haryana, India
3 ACOAST, Amity University Haryana, Gurugram, Haryana, India
*Address all correspondence to: shandilya.manish7@gmail.com
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
16
Palliative Care
[1] Brescia, F.J., et al., Pain, opioid use, 
and survival in hospitalized patients with 
advanced cancer. 1992. 10(1): p. 149-155.
[2] Caraceni, A. and M.J.C. Shkodra, 
Cancer pain assessment and classification. 
2019. 11(4): p. 510.
[3] Hjermstad, M.J., et al., Assessment and 
classification of cancer pain. 2009. 3(1): 
p. 24-30.
[4] Bruera, E., et al., The Edmonton 
staging system for cancer pain: preliminary 
report. 1989. 37(2): p. 203-209.
[5] Hølen, J.C., et al., Pain assessment 
tools: is the content appropriate for use in 
palliative care? 2006. 32(6): p. 567-580.
[6] Woodard, G.A., K.D. Jones, and D.M. 
Jablons, Lung cancer staging and 
prognosis, in Lung Cancer. 2016, 
Springer. p. 47-75.
[7] Kumar, P. and L.J.I.J.o.P. Tripathi, 
Challenges in pain assessment: Pain 
intensity scales. 2014. 28(2): p. 61.
[8] Cervero, F.J.P.T.o.t.R.S.o.L.B., 
Biological Sciences, Visceral nociception: 
peripheral and central aspects of visceral 
nociceptive systems. 1985. 308(1136): p. 
325-337.
[9] Woolf, C.J.B.J.o.A., Somatic pain--
pathogenesis and prevention. 1995. 75(2): 
p. 169-176.
[10] Gierthmühlen, J. and R. Baron. 
Neuropathic pain. in Seminars in 
Neurology. 2016. Thieme Medical 
Publishers.
[11] Lewis, T.J.B.M.J., Study of somatic 
pain. 1938. 1(4023): p. 321.
[12] Cervero, F.J.V.p.L., Laird JM. 1999. 
353: p. 2145-2148.
[13] Martin, L.A., N.A.J.J.o.p. Hagen, 
and s. management, Neuropathic pain in 
cancer patients: mechanisms, syndromes, 
and clinical controversies. 1997. 14(2): 
p. 99-117.
[14] Nicholson, B.J.T.C.j.o.p., Taxonomy of 
pain. 2000. 16(3 Suppl): p. S114-7.
[15] Adams, N., J. Ravey, and D.J.P. 
Taylor, Psychological models of chronic 
pain and implications for practice. 1996. 
82(2): p. 124-129.
[16] Linton, S.J. and W.S.J.P.t. Shaw, 
Impact of psychological factors in the 
experience of pain. 2011. 91(5): p. 
700-711.
[17] Khanna, R., A. Kumar, and 
R.J.I.J.o.P. Khanna, Brief pain inventory 
scale: An emerging assessment modality for 
orofacial pain. 2015. 29(2): p. 61.
[18] Kaur, A. and Y.J.C.J.o.T. Guan, 
Phantom limb pain: A literature review. 
2018. 21(6): p. 366-368.
[19] Jaaniste, T., et al., Why 
unidimensional pain measurement 
prevails in the pediatric acute pain context 
and what multidimensional self-report 
methods can offer. 2019. 6(12): p. 132.
[20] May, S. and M.J.F.m.r. Serpell, 
Diagnosis and assessment of neuropathic 
pain. 2009. 1.
[21] Jensen, M.P., et al., Cognitive testing 
and revision of the Pain Quality 
Assessment Scale. 2013. 29(5): p. 
400-410.
[22] Kumar, S.P.J.I.j.o.p.c., Utilization of 
brief pain inventory as an assessment tool 
for pain in patients with cancer: a focused 
review. 2011. 17(2): p. 108.
[23] Keller, S., et al., Validity of the brief 
pain inventory for use in documenting the 
outcomes of patients with noncancer pain. 
2004. 20(5): p. 309-318.
[24] Erdemoglu, A. and R.J.A.N.S. Koc, 
Brief Pain Inventory score identifying and 
References
17
Assessment and Management of Pain in Palliative Care
DOI: http://dx.doi.org/10.5772/intechopen.96676
discriminating neuropathic and 
nociceptive pain. 2013. 128(5): p. 
351-358.
[25] Cleeland, C., The brief pain 
inventory user guide. Houston, TX: 
Author. 2009.
[26] Bennett, M.J.P., The LANSS Pain 
Scale: the Leeds assessment of neuropathic 
symptoms and signs. 2001. 92(1-2): p. 
147-157.
[27] Fishbain, D.A., et al., Can the 
neuropathic pain scale discriminate 
between non-neuropathic and neuropathic 
pain? 2008. 9(2): p. 149-160.
[28] Rog, D.J., et al., Validation and 
reliability of the Neuropathic Pain Scale 
(NPS) in multiple sclerosis. 2007. 23(6): 
p. 473-481.
[29] Anzar, S., C. Koshy, and 
K.M.J.I.j.o.p.c. Abraham, Validation of 
the Malayalam version of Leeds assessment 
of neuropathic symptoms and signs pain 
scale in cancer patients in the Regional 
Cancer Centre, Thiruvananthapuram, 
Kerala, India. 2017. 23(3): p. 293.
[30] Bennett, M.I., et al., Using screening 
tools to identify neuropathic pain. 2007. 
127(3): p. 199-203.
[31] McHugh, M.L.J.B.m., Interrater 
reliability: the kappa statistic. 2012. 
22(3): p. 276-282.
[32] Krause, S.J. and M.-M.J.T.C.j.o.p. 
Backonja, Development of a neuropathic 
pain questionnaire. 2003. 19(5): p. 
306-314.
[33] Caraceni, A., et al., Breakthrough 
pain characteristics and syndromes in 
patients with cancer pain. An 
international survey. 2004. 18(3): p. 
177-183.
[34] Hagen, N.A., et al., The Alberta 
Breakthrough Pain Assessment Tool for 
cancer patients: a validation study using a 
delphi process and patient think-aloud 
interviews. 2008. 35(2): p. 136-152.
[35] Sperlinga, R., et al., A lberta B 
reakthrough P ain A ssessment T ool: A 
validation multicentre study in cancer 
patients with breakthrough pain. 2015. 
19(7): p. 881-888.
[36] Williams, P.L. and C.J.J.o.a.n. Webb, 
The Delphi technique: a methodological 
discussion. 1994. 19(1): p. 180-186.
[37] Arthur, J., et al., Assessing the 
prognostic features of a pain classification 
system in advanced cancer patients. 2017. 
25(9): p. 2863-2869.
[38] Koulouris, A.I., et al., Pain in 
patients with pancreatic cancer: 
prevalence, mechanisms, management and 
future developments. 2017. 62(4): p. 
861-870.
[39] Jung, B.F., et al., Neuropathic pain 
following breast cancer surgery: proposed 
classification and research update. 2003. 
104(1): p. 1-13.
[40] Cope, T., et al., Channelopathy 
contributes to proprioceptive deficits 
following chemotherapy. 2014. 596: 
p. 90-107.
[41] Falk, S., K. Bannister, and 
A.H.J.B.j.o.p. Dickenson, Cancer pain 
physiology. 2014. 8(4): p. 154-162.
[42] Marcin, C.J.F., Recent advances in 
understanding and managing cancer pain. 
2017. 6.
[43] Lacomba, M.T., et al., Incidence of 
myofascial pain syndrome in breast cancer 
surgery: a prospective study. 2010. 26(4): 
p. 320-325.
[44] Mirabile, A., et al., Pain 
management in head and neck cancer 
patients undergoing chemo-radiotherapy: 




[45] Bausewein, C., et al., Palliative care 
of adult patients with cancer. 2015. 
112(50): p. 863.
[46] Wiffen, P.J., et al., Opioids for 
cancer-related pain in children and 
adolescents. 2017(7).
[47] Roxburgh, C. and D.C.J.B.j.o.c. 
McMillan, Cancer and systemic 
inflammation: treat the tumour and treat 
the host. 2014. 110(6): p. 1409-1412.
[48] Calo, G. and L. David, Approval of 
oliceridine (TRV130) for intravenous use 
in moderate to severe pain in adults. 2020.
[49] Kata, V., et al., Opioid addiction, 
diversion, and abuse in chronic and cancer 
pain. 2018. 12(2): p. 124-130.
[50] Vardy, J. and M.J.J.o.c.O. Agar, 
Nonopioid drugs in the treatment of 
cancer pain. 2014.
